NASDAQ:DMACDiaMedica Therapeutics Stock Price, Forecast & News

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DMAC shares have increased by 18.5% and is now trading at $4.74. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics.

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for DiaMedica Therapeutics.

DiaMedica Therapeutics Inc (NASDAQ:DMAC) announced its earnings results on Wednesday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. View DiaMedica Therapeutics' earnings history.

2 Wall Street analysts have issued twelve-month price objectives for DiaMedica Therapeutics' stock. Their forecasts range from $14.00 to $15.00. On average, they expect DiaMedica Therapeutics' stock price to reach $14.50 in the next year. This suggests a possible upside of 205.9% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics.

News headlines about DMAC stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutDiaMedica Therapeutics.

DiaMedica Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 13,500 shares, an increase of 82.4% from the April 30th total of 7,400 shares. Based on an average daily trading volume, of 48,300 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the shares of the company are short sold. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include Concert Pharmaceuticals (CNCE), CymaBay Therapeutics (CBAY), Chiasma (CHMA), ProQR Therapeutics (PRQR), Affimed (AFMD), Spero Therapeutics (SPRO), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), Obseva (OBSV), REDHILL BIOPHAR/S (RDHL), OptiNose (OPTN), Abeona Therapeutics (ABEO), Northwest Biotherapeutics (NWBO), Fortress Biotech (FBIO) and XOMA (XOMA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Oncolytics Biotech (ONCY), vTv Therapeutics (VTVT), Adamis Pharmaceuticals (ADMP), Crispr Therapeutics (CRSP), Seelos Therapeutics (SEEL) and Vaxart (VXRT).

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (5.84%) and BlackRock Inc. (0.27%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View institutional ownership trends for DiaMedica Therapeutics.

DMAC stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, and BlackRock Inc.. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen. View insider buying and selling activity for DiaMedica Therapeutics.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $4.74.

DiaMedica Therapeutics has a market capitalization of $67.02 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe.

The official website for DiaMedica Therapeutics is www.diamedica.com.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]